Cases were classified as Control, AsymAD, or AD based on semi-quantitative measures of amyloid (CERAD) and tau (Braak) deposition as well as cognitive function near the time of death (supplemental Fig. S1) (12, 18). The gene discussed is MAPT; the disease is Alzheimer disease.